These include topical therapies such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase-4 (PDE-4) inhibitors, or topical Janus kinase (JAK) inhibitors which carry varying safety concerns ranging from skin atrophy, stinging/burning to black box warnings. Here, PDE4A is linked to skin atrophy.